Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cellectis SA (CMVLF)
:CMVLF
Holding CMVLF?
Track your performance easily
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
―Last Year’s EPS
-0.14Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 13, 2018
|% Change Since: -37.19%
|Next Earnings Date:Aug 01, 2018
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Cellectis, driven by strategic partnerships, financial strength, and progress in clinical trials. However, challenges include the de-prioritization of certain assets and delays in data release.Company Guidance
During the Cellectis Third Quarter 2024 Earnings Call, several key metrics were highlighted regarding the company's financial and operational guidance. Cellectis reported a cash position, including cash equivalents and short-term deposits, of $264 million as of September 30, 2024, a significant increase from $156 million at the end of 2023. This improvement was attributed to $140 million received from AstraZeneca as part of their equity investment, additional revenue from AstraZeneca milestones totaling $47 million (with $25 million upfront and $22 million from development milestones), and $16 million from the European Investment Bank. The company has successfully extended its cash runway into 2027, allowing it to focus on advancing its core clinical programs, UCART22 and UCART20x22, while de-prioritizing UCART123. This strategic realignment is intended to optimize resources and enhance the potential for success in their ongoing clinical trials and collaborations.Strategic Collaboration with AstraZeneca
Initiation of research and development activities for three programs under collaboration with AstraZeneca, including CAR T therapies for hematological malignancies and solid tumors, and in vivo gene therapy for genetic disorders.
Financial Milestones Achieved
Cellectis triggered $47 million under the AstraZeneca agreement, including $25 million upfront and $22 million from development milestones, enhancing the company's financial position.
Strong Cash Position
Cash, cash equivalents, and financial assets increased to $264 million as of September 30, 2024, up from $156 million at the end of 2023, due to significant investments and revenue inflows.
Positive Progress in Clinical Trials
Recruitment in BALLI-01 and NATHALI-01 studies is progressing well, with expectations to share Phase I data in 2025.
---
CMVLF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CMVLF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 04, 2024 | $1.99 | $1.99 | 0.00% |
| Aug 06, 2024 | $2.00 | $2.10 | +5.00% |
| May 28, 2024 | $2.68 | $2.61 | -2.61% |
| Mar 11, 2024 | $2.63 | $2.62 | -0.38% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cellectis SA (CMVLF) report earnings?
Cellectis SA (CMVLF) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Cellectis SA (CMVLF) earnings time?
Cellectis SA (CMVLF) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CMVLF EPS forecast?
Currently, no data Available
---